Literature DB >> 18484588

Impact of computed tomography screening for lung cancer on participants in a randomized controlled trial (NELSON trial).

Karien A M van den Bergh1, Marie-Louise Essink-Bot, Eveline M Bunge, Ernst Th Scholten, Mathias Prokop, Carola A van Iersel, Rob J van Klaveren, Harry J de Koning.   

Abstract

BACKGROUND: Computed tomography (CT) screening is an important new tool for the early detection of lung cancer. In the current study, the authors assessed the discomfort associated with CT scanning and the subsequent wait for results and health-related quality of life (HRQoL) over time.
METHODS: A total of 351 participants in the Dutch-Belgian randomized controlled trial for lung cancer screening in high-risk subjects (the NELSON trial) who had an appointment for a baseline CT scan were asked to complete questionnaires regarding their experienced discomfort and HRQoL before, 1 day after, and approximately 6 months after the CT scan. HRQoL was measured as generic HRQoL (12-item Short Form [SF-12] and EuroQol questionnaire [EQ-5D]), generic anxiety (State-Trait Anxiety Inventory [STAI-6]), and lung cancer-specific distress (Impact of Event Scale [IES]). Approximately 76.9% of the participants completed all 3 questionnaires.
RESULTS: Approximately 87% to 99% of participants reported experiencing no discomfort related to the CT scan. The median SF-12, EQ-5D, STAI-6, and IES scores did not appear to change relevantly over time. Approximately 46.0% and 51.3%, respectively, of the participants reported discomfort in connection with having to wait for the results of the CT scan and dreading those results. These patients had relevantly higher STAI-6 and IES scores (P < .01) (unfavorable) at all 3 assessments.
CONCLUSIONS: The current evaluation of the potential adverse effects of CT screening for lung cancer on HRQoL demonstrated no negative effects. However, waiting for the CT scan results was reported to be discomforting by approximately half of the participants. Minimizing the waiting time for the test results is therefore recommended. (c) 2008 American Cancer Society.

Entities:  

Mesh:

Year:  2008        PMID: 18484588     DOI: 10.1002/cncr.23590

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  35 in total

1.  The impact of radiologists' expertise on screen results decisions in a CT lung cancer screening trial.

Authors:  Marjolein A Heuvelmans; Matthijs Oudkerk; Pim A de Jong; Willem P Mali; Harry J M Groen; Rozemarijn Vliegenthart
Journal:  Eur Radiol       Date:  2014-11-04       Impact factor: 5.315

Review 2.  Lung cancer screening: an update, discussion, and look ahead.

Authors:  Peter J Mazzone
Journal:  Curr Oncol Rep       Date:  2010-07       Impact factor: 5.075

3.  The National Lung Screening Trial: overview and study design.

Authors:  Denise R Aberle; Christine D Berg; William C Black; Timothy R Church; Richard M Fagerstrom; Barbara Galen; Ilana F Gareen; Constantine Gatsonis; Jonathan Goldin; John K Gohagan; Bruce Hillman; Carl Jaffe; Barnett S Kramer; David Lynch; Pamela M Marcus; Mitchell Schnall; Daniel C Sullivan; Dorothy Sullivan; Carl J Zylak
Journal:  Radiology       Date:  2010-11-02       Impact factor: 11.105

4.  Quality of life and healthcare use in a randomized controlled lung cancer screening study.

Authors:  Peter J Mazzone; Nancy Obuchowski; Alex Z Fu; Michael Phillips; Moulay Meziane
Journal:  Ann Am Thorac Soc       Date:  2013-08

Review 5.  Screening for lung cancer with low-dose computed tomography: a review of current status.

Authors:  Henry M Marshall; Rayleen V Bowman; Ian A Yang; Kwun M Fong; Christine D Berg
Journal:  J Thorac Dis       Date:  2013-10       Impact factor: 2.895

6.  Optimisation of volume-doubling time cutoff for fast-growing lung nodules in CT lung cancer screening reduces false-positive referrals.

Authors:  Marjolein A Heuvelmans; Matthijs Oudkerk; Geertruida H de Bock; Harry J de Koning; Xueqian Xie; Peter M A van Ooijen; Marcel J W Greuter; Pim A de Jong; Harry J M Groen; Rozemarijn Vliegenthart
Journal:  Eur Radiol       Date:  2013-03-19       Impact factor: 5.315

7.  Glycoproteomic analysis of bronchoalveolar lavage (BAL) fluid identifies tumor-associated glycoproteins from lung adenocarcinoma.

Authors:  Qing Kay Li; Punit Shah; Yan Li; Paul O Aiyetan; Jing Chen; Rex Yung; Daniela Molena; Edward Gabrielson; Frederic Askin; Daniel W Chan; Hui Zhang
Journal:  J Proteome Res       Date:  2013-07-11       Impact factor: 4.466

Review 8.  Lung cancer screening.

Authors:  U Pastorino
Journal:  Br J Cancer       Date:  2010-04-27       Impact factor: 7.640

9.  CT scan screening is associated with increased distress among subjects of the APExS.

Authors:  Christophe Paris; Marion Maurel; Amandine Luc; Audrey Stoufflet; Jean-Claude Pairon; Marc Letourneux
Journal:  BMC Public Health       Date:  2010-10-26       Impact factor: 3.295

10.  Short-term health-related quality of life consequences in a lung cancer CT screening trial (NELSON).

Authors:  K A M van den Bergh; M L Essink-Bot; G J J M Borsboom; E Th Scholten; M Prokop; H J de Koning; R J van Klaveren
Journal:  Br J Cancer       Date:  2009-11-24       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.